Top

Published in:

01-02-2021 | Multiple Sclerosis | Review Article

Association between serum paraoxonase 1 activity and its polymorphisms with multiple sclerosis: a systematic review

Authors: Nader Salari, Shna Rasoulpoor, Amin Hosseinian-Far, Nazanin Razazian, Kamran Mansouri, Masoud Mohammadi, Aliakbar Vaisi-Raygani, Rostam Jalali, Shervin Shabani

Published in: Neurological Sciences | Issue 2/2021

Abstract

Background

Human serum paraoxonase (PON) is an enzyme that is synthesized by the liver and enters the bloodstream, and it is transmitted by high-density lipoproteins (HDL). Paraoxonase 1 (PON1) is a hydrolytic enzyme with a wide range of substrates and the ability to protect against lipid oxidation. In this study, due to the activity of PON1 in the brain and its antioxidant effects on the reduction of neurological disorders in the central nervous system, the role of PON1 and its polymorphisms related to multiple sclerosis has been examined to enhance treatment methods.

Methods

This article is a systematic review. In this study, the role of PON1 and its polymorphisms in multiple sclerosis (MS) has been investigated. Articles published in Persian and international databases of SID, Google Scholar, ISI (WoS), Magiran, PubMed, Scopus, IranDoc, Science Direct, and Iran Medix were examined, using the search keywords of Paraoxonase 1, polymorphism, multiple sclerosis, and PON1.

Results

PON1 is undoubtedly a potential factor in the pathogenesis of multiple sclerosis, and it plays an important role in protecting antioxidants in the blood. Oxidative stress and lipid peroxidation are factors in the pathogenesis of MS. Both inflammatory cytokines and oxidative stress have a detrimental effect on PON1. However, reducing the activity of PON1 may help to restore the pathogenesis of the disease.

Conclusion

Decreased PON1 activity and PON1 polymorphism are associated with several neurological diseases, including ischemic stroke, white matter lesions (WMLs), amyotrophic lateral sclerosis (ALS), dementia, and Parkinson’s disease. PON1-55M alleles in Italians and PON1-192Q alleles in Poles were associated with a high risk of MS. Moreover, PON1-55 and PON1-192 polymorphisms were not associated with MS onset age, nor its evolutionary type.

Nessler S, Brück W (2010) Advances in multiple sclerosis research in 2009. J Neurol 257(9):1590–1593PubMedPubMedCentral

Sluder JA, Newhouse P, Fain D (2002) Pediatric and adolescent multiple sclerosis. Adolesc Med Clin 13(3):461

Marrie RA (2004) Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3(12):709–718PubMed

Litvinov D, Mahini H, Garelnabi M (2012) Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 4(11):523–532PubMedPubMedCentral

Khersonsky O, Tawfik DS (2005) Structure−reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 44(16):6371–6382PubMed

Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 33(3):498–507PubMed

Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RBG, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS (2004) Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11(5):412–419PubMed

Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46(6):1239–1247PubMed

Moghtaderi A, Hashemi M, Sharafaddinzadeh N, Dabiri S, Moazeni-Roodi A, Ramroodi N, Zolfaghari M (2011) Lack of association between paraoxonase 1 Q192R polymorphism and multiple sclerosis in relapse phase: a case-control study. Clin Biochem 44(10–11):795–798PubMed

10.

Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, la du B (1999) Human serum paraoxonase (PON 1) is inactivated by oxidized low-density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26(7–8):892–904PubMed

11.

Leray E, Moreau T, Fromont A, Edan A (2016) Epidemiology of multiple sclerosis. Rev Neurol (Paris) 172(1):3–13

12.

Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri V et al (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler J 11(6):677–682

13.

Mazur A (1946) An enzyme in animal tissues capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphate. J Biol Chem 164(1):271–289PubMed

14.

Aldridge W (1953) Two types of esterase (A and B) hydrolyzing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem J 53:110–7

15.

Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3(1):73–76PubMed

16.

Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE (1991) Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 30(42):10141–10149PubMed

17.

Yeung DT, Josse D, Nicholson JD, Khanal A, McAndrew CW, Bahnson BJ et al (2004) Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1702(1):67–77

18.

Bystrická Z, Laubertová L, Ďurfinová M, Paduchová Z (2017) Methionine metabolism and multiple sclerosis. Biomarkers. 22(8):747–754PubMed

19.

Morales R, Berna A, Carpentier P, Contreras-Martel C, Renault F, Nicodeme M, Chesne-Seck ML, Bernier F, Dupuy J, Schaeffer C, Diemer H, van-Dorsselaer A, Fontecilla-Camps JC, Masson P, Rochu D, Chabriere E (2006) Serendipitous discovery and X-ray structure of a human phosphate binding apolipoprotein. Structure. 14(3):601–609PubMed

20.

Yeung DT, Smith JR, Sweeney RE, Lenz DE, Cerasoli DM (2007) Direct detection of stereospecific soman hydrolysis by wild-type human serum paraoxonase. FEBS J 274(5):1183–1191PubMed

21.

Yeung DT, Lenz DE, Cerasoli DM (2005) Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates. FEBS J 272(9):2225–2230PubMed

22.

Sidoti A, Antognelli C, Rinaldi C, D’Angelo R, Dattola V, Girlanda P, Talesa V, Amato A (2007) Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Mult Scler J 13(4):446–453

23.

Salari N, Mohammadi M, Vaisi-Raygani A, Abdi A, Shohaimi S, Khaledipaveh B, Daneshkhah A, Jalali R (2020) The prevalence of severe depression in Iranian older adult: a meta-analysis and meta-regression. BMC Geriatr 20(1):39–49PubMedPubMedCentral

24.

Draganov D, La Du BN (2004) Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedeberg's Arch Pharmacol 369(1):78–88

25.

Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, Tsui LC, Prochazka M (1998) Human PON2 gene at 7q21. 3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene. 213(1–2):149–157PubMed

26.

Ďurfinová MĎ, Bartová R, Procházková Ľ, Petrleničová D, Sýkora P, Repiská V (2015) Paraoxonase 1 activity and polymorphisms in multiple sclerosis patients. Biologia. 70(12):1672–1676

27.

Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H (2009) Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler J 15(3):399–402

28.

Zakrzewska-Pniewska B, Nojszewska M, Róg T, Pniewski J, Dorobek M, Styczyńska M, Szczudlik A (2013) Polymorphisms of paraoxonase 1 and 2 genes and the risk of multiple sclerosis in the Polish population. Neurol Neurochir Pol 47(1):49–52PubMed

29.

Cowan J, Sinton C, Varley A, Wians F, Haley R, Munford R (2001) Gene therapy to prevent organophosphate intoxication. Toxicol Appl Pharmacol 173(1):1–6PubMed

30.

Langemann H, Kabiersch A, Newcombe J (1992) Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 32(5):248–252PubMed

31.

Martínez C, García-Martín E, Benito-León J, Calleja P, Díaz-Sánchez M, Pisa D, Alonso-Navarro H, Ayuso-Peralta L, Torrecilla D, Agúndez JAG, Jiménez-Jiménez FJ (2010) Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis. NeuroMolecular Med 12(3):217–223PubMed

32.

Adkins S, Gan K, Mody M, La Du B (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52(3):598–608PubMedPubMedCentral

33.

Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJM, Durrington PN (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin-dependent diabetes mellitus. Atherosclerosis. 139(2):341–349PubMed

34.

Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, la du BN (2000) Human serum paraoxonase (pon1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28(11):1335–1342PubMed

35.

Gaidukov L, Tawfik DS (2005) High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry. 44(35):11843–11854PubMed

36.

Roest M, Van Himbergen TM, Barendrecht AB, Peeters PHM, Van Der Schouw YT, Voorbij HAM (2007) Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Investig 37(3):187–196

37.

Hassan MA, Al-Attas OS, Hussain T, Al-Daghri NM, Alokail MS, Mohammed AK et al (2013) The Q192R polymorphism of the paraoxonase 1 gene is a risk factor for coronary artery disease in Saudi subjects. Mol Cell Biochem 380(1–2):121–128PubMed

38.

Leviev I, Negro F, James RW (1997) Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 17(11):2935–2939PubMed

39.

Leviev I, James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20(2):516–521PubMed

40.

Cherry N, Mackness M, Durrington P, Povery A, Dippnall M, Smith T, Mackness B (2002) Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 359(9308):763–764PubMed

41.

Rozek LS, Hatsukami TS, Richter RJ, Ranchalis J, Nakayama K, McKinstry LA et al (2005) The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res 46(9):1888–1895PubMed

42.

Srinivasan SR, Li S, Chen W, Tang R, Bond MG, Boerwinkle E, Berenson GS (2004) Q192R polymorphism of the paraoxonase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community: the Bogalusa Heart Study. Atherosclerosis. 177(1):167–174PubMed

43.

van Himbergen TM, Roest M, de Graaf J, Jansen EH, Hattori H, Kastelein JJ et al (2005) Indications that paraoxonase-1 contributes to plasma high-density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 46(3):445–451PubMed

44.

Van Himbergen T, Van Tits L, Roest M, Stalenhoef A (2006) The story of PON1: how an organophosphate-hydrolyzing enzyme is becoming a player in cardiovascular medicine. Neth J Med 64(2):34–38PubMed

45.

Shin BS, Oh SY, Kim YS, Kim KW (2008) The paraoxonase gene polymorphism in stroke patients and lipid profile. Acta Neurol Scand 117(4):237–243PubMed

46.

Bassett C, Montine TJ (2003) Lipoproteins and lipid peroxidation in Alzheimer’s disease. J Nutr Health Aging 7(1):24–29PubMed

47.

Hadjigeorgiou GM, Malizos K, Dardiotis E, Aggelakis K, Dardioti M, Zibis A, Dimitroulias A, Scarmeas N, Tsezou A, Karantanas A (2007) Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions. J Orthop Res 25(8):1087–1093PubMed

48.

Compston A, Coles A (2008) Multiple sclerosis. Lancet (Lond, Engl) 372:1502–1517

49.

LeVine S (1992) The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses 39(3):271–274PubMed

50.

Menini T, Gugliucci A (2014) Paraoxonase 1 in neurological disorders. Redox Rep 19(2):49–58PubMed

51.

Koch M, Ramsaransing GS, Arutjunyan AV, Stepanov M, Teelken A, Heersema DJ et al (2006) Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 253(4):483–487PubMed

52.

Rodrigo L, Hernández AF, Lopez-Caballero JJ, Gil F, Pla A (2001) Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 137(2):123–137PubMed

53.

Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M (2003) Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 34(6):774–784PubMed

54.

Hein K, Köhler A, Diem R, Sättler MB, Demmer I, Lange P et al (2008) Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci Lett 436(1):72–76

55.

Newcombe J, Li H, Cuzner M (1994) Low-density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol Appl Neurobiol 20(2):152–162PubMed

56.

La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC et al (1999) On the physiological role (s) of the paraoxonases. Chem Biol Interact 119:379–388PubMed

57.

Aharoni A, Gaidukov L, Yagur S, Toker L, Silman I, Tawfik DS (2004) Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci 101(2):482–487PubMed

58.

Durić G, Svetel M, Nikolaevic S, Dragadević N, Gavrilović J, Kostić V (2007) Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson’s disease. Vojnosanit Pregl 64(1):25–30PubMed

59.

Diekstra FP, Beleza-Meireles A, Leigh NP, Shaw CE, Al-Chalabi A (2009) Interaction between PON1 and population density in amyotrophic lateral sclerosis. Neuroreport. 20(2):186–190PubMed

60.

Van Horssen J, Witte ME, Schreibelt G, De Vries HE (2011) Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta (BBA) - Mol Basis Dis 1812(2):141–150

Title: Association between serum paraoxonase 1 activity and its polymorphisms with multiple sclerosis: a systematic review
Authors: Nader Salari
Shna Rasoulpoor
Amin Hosseinian-Far
Nazanin Razazian
Kamran Mansouri
Masoud Mohammadi
Aliakbar Vaisi-Raygani
Rostam Jalali
Shervin Shabani
Publication date: 01-02-2021
Publisher: Springer International Publishing
Keyword: Multiple Sclerosis
Published in: Neurological Sciences / Issue 2/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04842-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association between serum paraoxonase 1 activity and its polymorphisms with multiple sclerosis: a systematic review

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2021

The diagnosis and prognostic value of plasma copeptin in traumatic brain injury: a systematic review and meta-analysis

Eye movements in general neurology and its subspecialties: introduction to the topical collection

Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction

Life with chronic pain during COVID-19 lockdown: the case of patients with small fibre neuropathy and chronic migraine

Correction to: Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia

Evaluation of serum uric levels in migraine